Clinical trials: Blood Protein Disorders
ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma.
- Trial name
- NCT05497804
- Testing
- Bone Marrow Aspiration and Biopsy, Carfilzomib, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well bortezomib works in treating patients with newly diagnosed multiple myeloma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00075881
- Testing
- bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoid Malignancies, Multiple Myeloma
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest.
- Conditions
- Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma
- Trial name
- PDX+Romi (NCT01947140)
- Testing
- Pralatrexate, Romidepsin
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Jennifer Amengual
Von Willebrand Disease
Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery
The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in adult patients with hereditary severe von…
- Trial name
- NCT02283268
- Testing
- Recombinant von Willebrand Factor (rVWF)
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 24 people
- Sponsor
- Baxalta now part of Shire
Multiple Myeloma
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
This study is for patients that have multiple myeloma that has come back or relapsed and their condition indicates a procedure called an Autologous Hematopoietic Stem Cell Transplantation (AHSCT).
- Trial name
- NCT01690143
- Testing
- Carfilzomib, Melphalan
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Multiple Myeloma
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
The purpose of the Phase 1 part of the study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of oprozomib in combination with pomalidomide and dexamethasone in adults with primary…
- Trial name
- NCT01999335
- Testing
- Oprozomib, Pomalidomide, Dexamethasone
- Where
- 17 sites in United States
- Volunteers
- 33 people
- Sponsor
- Amgen
Multiple Myeloma
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy…
- Trial name
- NCT04140162
- Testing
- Daratumumab, Lenalidomide, Bortezomib
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- University of Michigan Rogel Cancer Center
Healthy
Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
The purpose of this study is to assess the safety and tolerability of various regimens containing adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV), Modified Vaccinia Ankara (MVA)-Mosaic, and/or HIV type…
- Trial name
- NCT02315703
- Testing
- Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose
- Where
- 12 sites in United States, Rwanda and 3 more
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Multiple Myeloma and Plasma Cell Neoplasm
Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00609167
- Testing
- bortezomib, cyclophosphamide, dexamethasone
- Where
- 2 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic
Relapsed/Refractory Multiple Myeloma
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination…
- Trial name
- NCT06160609
- Testing
- Belantamab Mafodotin, GSK3174998
- Where
- 3 sites in Australia, Canada and 1 more
- Volunteers
- 9 people
- Sponsor
- GlaxoSmithKline
Hemophilia A
Early Prophylaxis Immunologic Challenge (EPIC) Study
The purpose of the study was to assess if a once-weekly prophylactic regimen of 25 IU/kg ADVATE started at or before 1 year of age and before the onset of a severe bleeding phenotype (ie, joint bleeding), together with the…
- Trial name
- EPIC (NCT01376700)
- Testing
- Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
- Where
- 19 sites in United States, Austria and 10 more
- Volunteers
- 22 people
- Sponsor
- Baxalta now part of Shire
Prostate Cancer, Multiple Myeloma
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering…
- Conditions
- Prostate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT04731844
- Testing
- Curcumin plus Piperine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Hypertension, Hypercholesterolemia
Clinical Trial of Protein and Blood Pressure
The purpose of this randomized, double-blind, controlled trial is to examine the effect of soybean protein supplementation on blood pressure in persons with prehypertension or stage-1 hypertension.
- Trial name
- ProBP (NCT00107744)
- Testing
- Soy protein-milk protein-carbohydrate, Milk protein-carbohydrate-soy protein, Carbohydrate-soy protein-milk protein
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Tulane University
Plasma Cell Leukemia, Recurrent Multiple Myeloma
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
This pilot clinical trial studies whether using high throughput drug sensitivity and genomics data is feasible in developing individualized treatment in patients with multiple myeloma or plasma cell leukemia that has come back or…
- Conditions
- Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT03389347
- Testing
- Biospecimen Collection, High Throughput Screening, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Washington
Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.
- Trial name
- NCT02675452
- Testing
- AMG 176, Azacitidine, Itraconazole
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 141 people
- Sponsor
- Amgen
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).
- Trial name
- NCT00573391
- Testing
- Velcade, Thalidomide, and Dexamethasone, Velcade, Melphalan, and Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Arkansas
Acute Leukemia, Chronic Leukemia
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
In an attempt to reduce relapse risk and improve outcomes following haploidentical transplantation for patients with high risk hematologic malignancies, the investigators will implement several strategies to augment the well…
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas
- Trial name
- NCT02169791
- Testing
- MLN9708
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Northside Hospital, Inc.
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Congenital Bleeding Disorder, Haemophilia A
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
This trial is conducted in Asia, Europe, Japan, Oceania, North America and South America. The aim of the trial is to investigate the safety and efficacy of turoctocog alfa (N8) in Haemophilia A patients.
- Trial name
- NCT00984126
- Testing
- turoctocog alfa
- Where
- 57 sites in United States, Brazil and 18 more
- Volunteers
- 214 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.